BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

BTIG analyst Julian Harrison has reiterated a Buy rating on Nektar Therapeutics (NASDAQ: NKTR) and has maintained a price target of $178 for the stock. This endorsement suggests confidence in the company's future performance.